Jennifer Sinnott
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (13)
Background: Despite prevalent use of SEER-Medicare data to study uterine cancer treatment patterns and survival, concordance between SEER and Medicare claims has not been a focus of prior research. We assessed agreement between SEER and Medicare claims, predictors of disagreement between sources, and associations between treatment (identified in SEER- vs. Medicare) and survival. Methods: Patients diagnosed with uterine cancer between 2000 and 2019 were identified using the SEER-Medicare linked database. We calculated kappa statistics to assess agreement between the two data sources for receipt of hysterectomy with or without bilateral salpingo-oophorectomy (BSO), hysterectomy with BSO, lymphadenectomy, external beam radiotherapy (EBRT), vaginal brachytherapy (VBT), and chemotherapy. For each treatment type, we examined temporal trends in the kappa and used multivariable-adjusted logistic regression to examine predictors of disagreement. Treatment hazard ratios in Cox proportional hazards regression models using treatment information from SEER vs. Medicare were compared. Results: For each treatment, we excluded patients with unknown SEER information, resulting in variable sample sizes. Agreement was lowest for hysterectomy with BSO (kappa=0.71) and highest for lymphadenectomy and chemotherapy (kappas=0.85). Temporal variation was evident, with lymphadenectomy, EBRT, and VBT agreement dropping in recent years. Black race, younger age at diagnosis, high-risk histology, and advanced stage were associated with higher disagreement odds for certain treatments. Associations between treatment identified in SEER vs. Medicare and survival outcomes were similar. Conclusions: Treatment agreement between SEER and Medicare was high. Impact: Our results support use of both data sources for uterine cancer treatment-survival analyses.
Year:
2026
Year:
2026
Year:
2026
Importance Racial and ethnic disparities in uterine cancer survival are well-documented; however, limited data exist regarding the interplay of geography, diversity, and race and ethnicity in survival disparities. Objective To examine associations of race and ethnicity with uterine cancer–specific survival according to geographic region and regional diversity. Design, Setting, and Participants This retrospective cohort study included patients with uterine cancer diagnosed from 2000 to 2019, from 17 Surveillance, Epidemiology, End Results registries, grouped by US location and ranked according to the US Census Bureau’s Diversity Index (DI; range, 0%-100%; higher values indicate greater diversity), a metric of racial and ethnic composition. Analyses were conducted from June 8, 2024 to October 30, 2024. Exposures Race and ethnicity of patients with uterine cancer, categorized as Asian, Black, Hispanic, and White. Main Outcomes and Measures Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for multivariable-adjusted associations of race and ethnicity with uterine cancer–specific survival (primary outcome) in the overall sample and stratified by location. Location-stratified models were used to examine whether associations of race and ethnicity with survival varied by tumor characteristics. Results Among 162 500 patients with uterine cancer (median [IQR] age at diagnosis, 61 [54-69] years), there were 12 226 Asian patients (7.5%), 14 007 Black patients (8.6%), 20 799 Hispanic patients (12.8%), and 115 468 White patients (71.1%). Cancer-specific survival was better among Asian patients (HR, 0.91; 95% CI, 0.86-0.97), worse among Black patients (HR, 1.34; 95% CI, 1.28-1.40), and not different among Hispanic patients (HR, 1.01; 95% CI, 0.97-1.06) compared with White patients. Location-stratified analyses found worse uterine cancer–specific survival among Black patients compared with White patients in both higher DI locations (California: HR, 1.34; 95% CI, 1.25-1.44; DI, 69.7%; New Jersey: HR, 1.34; 95% CI, 1.21-1.50; DI, 65.8%; Georgia: HR, 1.39; 95% CI, 1.26-1.53; DI = 64.1%) and lower DI locations (Louisiana: HR, 1.34; 95% CI, 1.16-1.54; DI = 58.6%; Connecticut: HR, 1.42; 95% CI, 1.17-1.72; DI, 55.7%; Iowa: HR, 1.71; 95% CI, 1.01-2.89; DI, 30.8%). Hispanic patients, compared with White patients, had worse survival in Hawaii (HR, 2.09; 95% CI, 1.28-3.42) and Georgia (HR, 1.44; 95% CI, 1.13-1.82), whereas Asian patients had better survival than White patients in California (HR, 0.91; 95% CI, 0.84-0.97). In locations demonstrating survival disparities between Black and White patients, these patterns were evident in most tumor characteristic–defined strata. Conclusions and Relevance In this cohort study of patients with uterine cancer, racial and ethnic disparities in survival within specific geographic areas were identified. Targeted research may reduce national disparities.
Year:
2025
Introduction: Racial disparities in uterine cancer treatment and survival are well-documented. Despite the growing use of the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database for assessment of treatment-related uterine cancer survival effects, concordance between the two sources of radiation and chemotherapy information (medical record abstraction in SEER and billing claims in Medicare) has not been evaluated among uterine cancer patients. We aimed to assess agreement between these sources and examine potential racial/ethnic differences in concordance. Methods: Non-Hispanic Black (NHB) and non-Hispanic White (NHW) patients diagnosed with uterine cancer between 2000 and 2019 were identified using the SEER-Medicare linked database. In SEER, chemotherapy is categorized as no/unknown, yes, or missing and radiation type can be categorized as none, external beam radiation therapy (EBRT), vaginal brachytherapy (VBT), EBRT plus VBT, or missing. We identified radiation type and chemotherapy receipt using various claim types [e.g., Healthcare Common Procedure Coding System (HCPCS)] across multiple datasets [e.g., National Claims History (NCH)]. Administration of radiation or chemotherapy was established when we identified at least one claim 6 months before or 9 months after the SEER diagnosis date. We then calculated the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and Kappa statistics for EBRT, VBT, and chemotherapy using Medicare claims as the presumed gold standard. We stratified the analysis by race/ethnicity to evaluate potential variation by race/ethnicity. Results: Sample sizes varied by treatment. In the radiation analyses, we excluded 23,923 uterine cancer patients with unknown radiation receipt in SEER, leaving 29,035 patients (8.3% NHB, 91.7% NHW) for analysis. Sensitivity was high for both EBRT and VBT (>88%), with little variation by race; however, specificity for EBRT was low among NHB (20.0%) and NHW (24.4%) women, leading to poor agreement between the two sources (EBRT Kappa: 0.23 for NHB and 0.30 for NHW). PPV and NPV were moderate for EBRT and VBT (>62.0%). In the chemotherapy analysis, we excluded 20,923 uterine cancer patients with missing SEER chemotherapy data, leaving 32,035 uterine cancer patients (8.4% NHB, 91.6% NHW). Sensitivity was high for NHB (95.9%) and NHW (97.2%) patients; however, specificity (≤36%) and agreement (Kappa: ≤0.42) were low. PPV and NPV of chemotherapy were high (>68.0%). Conclusions: Agreement between SEER and Medicare varied by treatment type; however, we did not observe meaningful differences in performance characteristics by race. Future analyses will examine treatment claims data among the sizable subset of patients with missing SEER treatment. In addition, we will compare coarse SEER treatment variables (i.e., no vs yes) with more detailed, claims-defined treatment scenarios (i.e., receipt of guideline-recommended 4-6 cycles of chemotherapy) to assess the accuracy and quality of treatment data captured by SEER. Citation Format: Ashley S. Felix, Jiahao Ping, Caitlin E. Meade, Simran A. Kanal, Tasleem J. Padamsee, Macarius M. Donneyong, Kemi M. Doll, Jennifer A. Sinnott. A comparison of surveillance, epidemiology, end results (seer) and medicare claims-derived radiation and chemotherapy treatment among Black and White patients with uterine cancer [abstract]. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr C003.
Year:
2025
Purpose: Hysterectomy with bilateral salpingo-oophorectomy (BSO) is the cornerstone of uterine cancer treatment. The Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database provides two sources of surgery information: medical record abstraction (SEER) and billing claims (Medicare). Concordance between these two sources has not been evaluated among uterine cancer patients. Given the increasing use of SEER-Medicare for assessment of treatment-related uterine cancer survival effects, an understanding of the concordance of these two sources is needed. Methods: Patients diagnosed with uterine cancer between 2000 and 2019 were identified using the SEER-Medicare linked database. We calculated sensitivity, specificity, positive predictive value, negative predictive value, and Kappa statistics for receipt of hysterectomy with or without BSO and receipt of hysterectomy with BSO using Medicare claims as the presumed gold standard. Analyses were repeated stratified by race, histology, and stage. Results: A total of 34, 904 uterine cancer patients [9% Black, mean (standard deviation) age at diagnosis: 74.6 (6.7) years] were included in the comparison of surgery derived in SEER vs. Medicare claims, after excluding 39.7% with unknown surgery status from SEER. A total of 30, 943 patients were identified as having hysterectomy with or without BSO in both the claims and SEER, resulting in a moderately strong sensitivity [78.4%, 95% confidence interval (CI)= 77.1%, 79.8%]. A total of 29, 733 patients were identified as having hysterectomy with BSO in both the claims and SEER, resulting in a sensitivity of 69.5% (95% CI= 68.1%, 70.8%). For both procedures, lower sensitivity was noted for non-Hispanic Whites, those diagnosed with grade 1 endometrioid, or those diagnosed with stage 1 disease. Specificity was high for both treatment types and across race, histology, and stage categories (>96.9%). In cases where there was discordance between claims and SEER, claims were more likely to report a corresponding insurance claim when there was no corresponding surgery indication in SEER. Conclusions: In the subset of uterine cancer patients with known SEER surgery, SEER data reliably identified receipt of hysterectomy with or without BSO and hysterectomy with BSO; however, variations according to patient characteristics were observed. Of concern is the large proportion of unknown surgery data in SEER, which has implications for research aimed at estimating the population prevalence of surgery and investigations comparing outcomes between surgically and non-surgically treated patients. Investigations of the origins of unknown SEER surgery data are warranted. Citation Format: Ashley S. Felix, Caitlin E. Meade, Qinhan Hu, Anusha M. Vable, Tasleem J. Padamsee, Marcarius Donneyong, Kemi M. Doll, Jennifer A. Sinnott. Ascertainment of uterine cancer surgery in the Surveillance, Epidemiology, End Results (SEER)-Medicare linked database: Comparison of SEER and claims data [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2296.
Year:
2025
Year:
2025
Neuromyelitis optica spectrum disorders (NMOSD) comprise autoimmune diseases imposing substantial disability. We compared an NMOSD-targeted disability assessment of mobility, vision, and self-care domains (individually and composite) with the multiple sclerosis-targeted Expanded Disability Status Scale (EDSS) to assess NMOSD disease burden. An overall cohort ( n = 505) and a subset of these patients with an enriched dataset ( n = 198) were analyzed from the CIRCLES longitudinal, observational database of patients with AQP4-IgG–seropositive or –seronegative NMOSD in North America. Multinomial modeling was used to identify temporal correlates of disability improvement, stability, and worsening. Prior on-study relapse correlated with worsening mobility (OR, 3.08; 95% CI: 1.61–5.90), vision (OR, 3.99; 95% CI: 2.03–7.86), self-care disability (OR, 1.90; 95% CI: 1.07–3.38), and mean composite index disability (OR, 4.20; 95% CI: 1.71–10.34). Higher vision disability was associated with Black race, shorter time on-study, and AQP4-IgG–seropositive status in patients ≥ 18 years ( p < 0.05). Disease onset phenotype and sex correlated with pain interference ( p < 0.05). These correlates of NMOSD disability were undetected by EDSS. The CIRCLES real-world experience supports the need for NMOSD-specific disability assessment to improve recognition of disease burden, facilitate proactive clinical management, offer insights into resilience, and inform clinical trial design.
Year:
2024
Objective We examined associations among changes in anthropometry, regional adiposity, and inflammatory markers in Black and White women participating in intentional weight loss. Methods A total of 104 women with BMI ≥ 25 kg/m 2 self‐selected bariatric surgery ( n = 66) or a diet and exercise program ( n = 38). Anthropometric, dual‐energy x‐ray absorptiometry‐quantified regional adiposity, and inflammatory markers (C‐reactive protein [CRP], tumor necrosis factor α [TNF‐α], soluble TNF receptor I [sTNFRI], sTNFRII, interleukin [IL]‐6, and soluble IL‐1 receptor antagonist) were measured at baseline and 6 months. Results Weight, BMI, visceral adipose tissue, and regional (android and gynoid) adiposity declined in the bariatric surgery group. Among bariatric surgery participants, Black women experienced declines of lesser magnitude in terms of weight and BMI than White women, but changes in regional adiposity and visceral adipose tissue did not differ. In the bariatric surgery group, decreases in weight and BMI were associated with decreases in CRP and IL‐6 among White women, but not Black women. Decreases in weight, BMI, and android fat were associated with increases in TNF‐α, sTNFRI, and sTNFRII among Black women, but not White women. Conclusions Decreases in anthropometry and adiposity were observed among Black and White bariatric surgery participants; however, associations among changes in adiposity, anthropometry, and inflammation differed by race.
Year:
2024
Background: Black-White mortality disparities are well-established and continue to widen over time among women diagnosed with endometrial cancer (EC). Yet, few studies have explored the existence or sources of racial/ethnic disparities in EC survival among Hispanic, American Indian/Alaska Native (AI/AN), Asian, and Native-Hawaiian/Pacific Islander (NH/PI) women. EC survival disparities across racial and ethnic groups have been suggested to be linked to differences in sociodemographic, clinical, and access to care characteristics. We examined how these individual- and area-level factors influence the presence of racial/ethnic disparities among women with EC. Methods: Participants were diagnosed between 2004 and 2019 with stages 1A through 4B endometroid and non-endometroid EC in the National Cancer Database (NCDB). Race was categorized as non-Hispanic white (NHW), non-Hispanic black (NHB), Hispanic, Asian, NH/PI, and AI/AN. We performed Oaxaca-Blinder decompositions of the log overall survival (OS) time assuming an accelerated failure time model with Weibull error, which decomposes observed differences in log survival time into parts potentially explained by differences in measured prognostic factors and differences not explained by measured variables. We examined the following classes of prognostic factors: age at diagnosis, zip code-level demographics (educational attainment, average income, and rurality), access to care (insurance status, facility type and location, treatment delay), Charlson comorbidity score, tumor characteristics (stage and histology), and guideline-concordant treatment (GCT). White women were the comparison group in all decompositions. Results: Compared with NHW women (N=121,069; estimated overall survival for average covariates values (eOS)=19.7 years) eOS was significantly shorter among NHB women (N=15,855; eOS=9.9 years); longer among Asian women (N=5,098; eOS=42.7 years); longer among Hispanic women (N=9,671; eOS=25.9 years); and not significantly different in NH/PI (N=536; eOS=24.8 years) or AI/AN women (N=551; eOS=17.0 years). Measured covariates explained 76.7% of the difference for NHB women (p<0.001); 19.7% for Asian women (p<0.001); and did not significantly explain the difference for Hispanic women (8.4%; p=0.14). Factors significantly contributing to the observed differences for NHB women were tumor characteristics (61.5%); access to care (6.6%); zip code-level demographics (5.1%); comorbidity (3.9%); age (-1.8%); and GCT (1.5%). Significant factors for Asian women were age (16.6%); tumor characteristics (-6.0%); zip code-level demographics (4.7%); access to care (3.0%); and comorbidity (1.6%). Significant factors for Hispanic women were age (45.2%); tumor characteristics (-17.9%); access to care (-13.4%); comorbidity (-2.0%); and GCT (-1.0%). Conclusions: Contributors to EC survival disparities vary by race/ethnicity and strongly implicate the need for research to identify how disparities arise to tailor interventions to reduce survival gaps. Citation Format: Jordyn A. Brown, Jennifer A. Sinnott, Ziyu Gao, Caitlin E. Meade, Macarius M. Donneyong, Tasleem J. Padamsee, Ashley S. Felix. Decomposing racial and ethnic disparities in endometrial cancer survival [abstract]. In: Proceedings of the AACR Special Conference on Endometrial Cancer: Transforming Care through Science; 2023 Nov 16-18; Boston, Massachusetts. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(5_Suppl):Abstract nr A003.
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (5)
Tasleem Padamsee
Associate Professor
Ohio State University
Britton Trabert
Associate Professor
University of Utah
Allison Quick
Ohio State University
Shannon Gillespie
Associate Professor
Ohio State University
Macarius M. Donneyong
Associate Professor
Ohio State University
Make your next move.
Prepare your application
Review drafts before you send them.